Medtronic plc — FY2019 Form 10-K summary
Reporting period: Fiscal year ended April 26, 2019 (52 weeks). The filing also reports fourth-quarter results; the company’s fiscal-year end is not the calendar year-end. Medtronic is a global medical technology company with four reportable groups: Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies, and Diabetes.
Financial performance
| Metric | FY2019 | FY2018 | Change |
|---|---|---|---|
| Net sales | $30.557 billion | $29.953 billion | +2% |
| Operating profit | $6.268 billion | $6.640 billion | -6% |
| Net income attributable to Medtronic | $4.631 billion | $3.104 billion | +49% |
| Diluted earnings per share | $3.41 | $2.27 | +50% |
| Operating cash flow | $7.007 billion | $4.684 billion | +$2.323 billion |
| Free cash flow (non-GAAP) | $5.873 billion | $3.616 billion | +$2.257 billion |
Gross margin was approximately 70.0% (versus 69.7%); operating margin was approximately 20.5% (versus 22.2%). Net income and EPS comparisons are heavily affected by the $2.4 billion U.S. tax-reform charge recorded in FY2018. FY2019 non-GAAP diluted EPS was $5.22, up from $4.77; non-GAAP nominal tax rate was 13.6%, compared with 14.7%.
- Group sales: Cardiac and Vascular $11.505 billion (+1%); Minimally Invasive Therapies $8.478 billion (-3%); Restorative Therapies $8.183 billion (+6%); Diabetes $2.391 billion (+12%). The Minimally Invasive Therapies comparison reflects the prior divestiture of businesses.
- Growth drivers: Restorative Therapies and Diabetes led group growth. Emerging-market sales increased 6%; U.S. sales increased 2%, while non-U.S. developed-market sales were flat. Currency reduced FY2019 sales by $455 million across non-U.S. developed and emerging markets.
Balance sheet, liquidity, and capital allocation
- At April 26, 2019, cash and cash equivalents were $4.393 billion and current investments were $5.455 billion. Current assets totaled $21.967 billion against current liabilities of $8.472 billion.
- Total debt was approximately $25.3 billion: $838 million current and $24.486 billion long-term, versus approximately $25.8 billion a year earlier. Shareholders’ equity was $50.091 billion.
- FY2019 financing included €7.0 billion of Euro-denominated notes, producing approximately $7.8 billion in net proceeds. Proceeds funded tender offers and early redemption of $6.4 billion of existing notes; the company recorded a $485 million debt-extinguishment loss.
- No commercial paper or credit-facility borrowings were outstanding at year-end. The company stated available liquidity was sufficient for foreseeable operating needs for at least 12 months. Long-term ratings remained S&P A and Moody’s A3.
- Dividends declared were $2.00 per share, up from $1.84. The company repurchased 31 million shares during FY2019 and had approximately $7.2 billion remaining under repurchase authorizations.
Material changes and unusual items
- Sales grew modestly, while operating profit declined, partly reflecting higher restructuring costs, litigation charges, and the $485 million debt-extinguishment charge. Interest expense rose to $1.444 billion from $1.146 billion.
- FY2019 operating cash flow improved, with management citing operating-margin expansion, lower tax and interest payments, and extended supplier payment terms. FY2018 cash flow had been reduced by a $1.1 billion IRS advance payment related to Puerto Rico transfer-pricing litigation.
- The 2017 sale of Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses generated $6.1 billion of proceeds and a $697 million gain in FY2018; the divested businesses contributed $0.6 billion of FY2018 sales versus $2.4 billion in FY2017.
- The company acquired Mazor Robotics and EPiX Therapeutics during FY2019. Acquisition cash outflows, net of cash acquired, were $1.827 billion.
- The Enterprise Excellence restructuring program is expected to generate more than $3.0 billion in annual gross savings by FY2022, with approximately $500 million to $700 million of annual savings expected each fiscal year through FY2022. Estimated pre-tax restructuring charges are $1.6 billion to $1.8 billion, with cash outlays substantially complete by FY2023.
Outlook, risks, and contingencies
- The filing does not provide a clear consolidated FY2020 revenue or EPS guidance figure. Management’s outlook emphasizes therapy innovation, expansion in emerging markets, and value-based healthcare solutions.
- Management identified pricing and reimbursement pressure, competition and product launches, regulatory approval timing, procedure volumes, currency fluctuations, and changes in product mix as risks to performance.
- A sterilization supplier facility closure affected Minimally Invasive Therapies products. Management was rerouting supply and expected full sterilization capacity late in the first quarter of FY2020.
- Regulatory matters include the continuing FDA consent decree related to the SynchroMed pump and Neuromodulation quality system, with audits and reports required through 2020, as well as FDA warning-letter/Form-483 matters involving TYRX, HeartWare, and Blackwell ICD manufacturing and design processes.
- Accrued litigation was approximately $0.5 billion at year-end, down from $0.9 billion. The filing cautions that actual outcomes may differ materially from accruals. Matters include pelvic mesh claims, an environmental remediation case involving the Penobscot River, ongoing government information requests, and tax disputes concerning Puerto Rico income allocation. A jury verdict of approximately $112 million in the Sasso dispute was being appealed; the company said it did not consider a loss probable.
- Other material risks include product quality and liability, supply interruptions, cybersecurity and privacy requirements, integration of acquisitions, substantial debt obligations, and changes or expiry of tax incentives. The company reported effective disclosure controls and internal control over financial reporting; its auditor issued unqualified opinions.
Investor facts to verify
- Separate underlying operating growth from divestiture effects, currency headwinds, and unusual tax or financing items; review the company’s non-GAAP reconciliations.
- Track delivery of Enterprise Excellence savings against the $1.6 billion to $1.8 billion restructuring-cost estimate and the FY2022 savings target.
- Monitor sterilization capacity recovery, FDA corrective actions, and the status of the SynchroMed consent decree.
- Review developments in Puerto Rico tax litigation, other tax examinations, pelvic mesh claims, and environmental proceedings, including possible cash and earnings effects.
- Assess debt maturities, refinancing costs, liquidity, and capital returns alongside acquisition spending and operating cash flow.